For example, previous studies showed that the combination of STING agonists and TLR7/8 agonists can cause stronger antigen cross-presentation in tumor immunotherapy, leading to significant tumor regression [42,43], and has a better anti-tumor effect than single-agent therapy. The gene discussed is TLR7; the disease is neoplasm.